AI: DeepSeek (deepseek-chat)

Q: {
  "prompt": "Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\n\nFor each recommendation, specify:\n1. The type of recommendation:\n   - Additional information needed (history/examination/investigations)\n   - Improved patient advice (options/statistics/patient information)\n   - Different management plan\n2. The specific recommendation\n3. The reason for the recommendation (referencing the guideline)\n\nCategorize each recommendation by importance:\n- Very Important: Critical for patient safety or guideline compliance\n- Somewhat Important: Significant for optimal care but not critical\n- Less Important: Would improve care but not essential\n- Unimportant: Minor suggestions that could be considered\n\nFormat the response as follows:\n\n### Very Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Somewhat Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Less Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Unimportant Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\nClinical Note:\nSITUATION: 35-year-old G4P2+1 at 28+5 weeks gestation with major placenta previa and recent bleeding episode requiring management\n\nBACKGROUND: Mrs Ahmed has known complete placenta previa diagnosed at 20-week anomaly scan, where placenta was noted to completely cover the cervical os. She has been managed with pelvic rest and regular monitoring. Yesterday evening she experienced sudden onset bright red vaginal bleeding, described as 'heavy like a heavy period' lasting approximately 20 minutes before settling. No associated pain, no contractions, good fetal movements felt. This is her second bleeding episode - first was at 24 weeks requiring overnight observation. Obstetric history: 2 previous caesarean sections (emergency then elective), 1 first trimester miscarriage requiring ERPC. Significant risk factors for placenta previa include previous uterine surgery and maternal age. She has been compliant with activity restrictions and regular antenatal care.\n\nASSESSMENT: On examination, patient appears well, slightly anxious about bleeding. Vital signs stable: BP 118/72 mmHg, HR 88 bpm, temp 36.6Â°C. Abdomen soft, non-tender, fundal height 29cm. No current bleeding visible, small clots in pad from earlier episode. No abdominal pain or uterine tenderness. CTG shows reassuring fetal heart rate pattern with baseline 145 bpm, good variability, no decelerations. Recent ultrasound confirms complete placenta previa with placental edge 0mm from internal os. No evidence of placental abruption. Hemoglobin 10.8 g/dL (down from 11.4 g/dL last month), other bloods normal. Kleihauer-Betke test negative (Rh positive mother).\n\nRECOMMENDATION: Admission for observation and surveillance given significant bleeding episode. IV access established, cross-match for 4 units of blood. Antenatal corticosteroids administered for fetal lung maturity given risk of early delivery. Strict bed rest initially, then gradual mobilization if no further bleeding. Daily monitoring with CTG and maternal observations. Serial hemoglobin monitoring. Emergency caesarean section if further significant bleeding occurs. Elective caesarean section planned for 36-37 weeks if no further complications. Anesthetic consultation arranged given high-risk nature and potential for emergency delivery. Blood transfusion service informed of high-risk patient.\n\nGuideline:\n[ID] bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf\nTitle: BJOG - 2022 - Stock - Antenatal corticosteroids to reduce neonatal morbidity and mortality.pdf\nContent: Antenatal corticosteroids given within seven days prior to preterm birth reduce perinatal and neonatal death and respiratory distress syndrome. For women undergoing planned caesarean birth between 37+0 and 38+6 weeks, an informed discussion should take place about the potential risks and benefits of corticosteroids. Corticosteroids should be offered to women between 24+0 and 34+6 weeks' gestation in whom imminent preterm birth is anticipated. Women with twins and triplets should also be offered corticosteroids. Birth should not be delayed for corticosteroids if it impacts the health of the woman or baby. Antenatal corticosteroids should be offered to women with preterm prelabour rupture of membranes. Corticosteroids reduce neonatal death when given within 48 hours prior to birth, and benefits are still seen if given within 24 hours of birth.\n\nAntenatal corticosteroids should be considered for women at risk of preterm birth between 35+0 to 36+6 weeks gestation. Steroids have short-term respiratory benefits for the neonate but may increase the risk of neonatal hypoglycemia. The use of corticosteroids in late preterm birth should be carefully weighed for its risks and benefits. In multiple pregnancies, targeted corticosteroids for early birth should be considered, as there is little evidence of benefit in twins compared to singletons. Women with diabetes should not be excluded from receiving corticosteroids, but additional insulin and close monitoring are recommended. Antenatal corticosteroids should not delay birth if it is necessary for the health of the woman or baby. In pregnancies complicated by fetal growth restriction, pre-eclampsia, or antepartum hemorrhage, corticosteroids may be considered if imminent preterm birth is likely. Women should be informed about the lack of evidence for the use of corticosteroids in small-for-gestational-age babies.\n\nAntenatal corticosteroids should be offered to women with PPROM who are at increased risk of preterm birth. There is limited evidence to recommend repeat courses of antenatal corticosteroids if a woman remains at imminent risk of preterm birth seven days after administration. The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly. Antenatal corticosteroids are most effective when given within 48 hours prior to birth, with benefits seen within 24 hours of birth. They are most effective in reducing RDS in pregnancies that birth between 24 hours and 7 days of administration of the second dose.\n\nAntenatal corticosteroids have shown significant reductions in cases of RDS and cerebroventricular hemorrhage among infants born within specific time frames after administration. There is a reduction in fetal and neonatal death for births within 24 hours to seven days after administration. However, caution is advised in interpreting the data due to limitations in subgroup analyses. Population-based cohort studies support the early effects of antenatal corticosteroids, with the largest effect seen 24 hours to seven days after the first injection. Concerns about potential risks to both women and babies include effects on maternal blood glucose levels, fetal growth, neonatal hypoglycemia, long-term metabolic and neurological consequences, and potential impacts on brain development. WHO recommends offering antenatal corticosteroids only when minimum standards of maternal and neonatal hospital services are available.\n\nAntenatal corticosteroids should not be delayed in serious maternal or fetal conditions. In the presence of systemic infection, the use of corticosteroids should be carefully balanced due to the risk of exacerbating the infection. Repeat courses of corticosteroids may not reduce serious morbidity but can lead to smaller babies. The maximum number of corticosteroid courses in pregnancy should not exceed three. Research is needed to determine the effectiveness of corticosteroids in various conditions and to investigate potential off-target effects. Recommendations for future research include determining the effectiveness of corticosteroids in reducing neonatal morbidity in elective caesarean births at term and investigating the safety and effectiveness of steroids in multiple pregnancies and women with diabetes. Auditable topics include discussions about corticosteroids in planned caesarean births and the proportion of women offered corticosteroids for preterm birth. Support groups and useful links are provided for further information.\n\nAntenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. Managing hyperglycaemia during antenatal steroid administration, labour, and birth in pregnant women with diabetes. Should antenatal corticosteroids be considered in women with gestational diabetes before planned late gestation caesarean section. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Multiple courses of antenatal corticosteroid therapy in patients with preterm premature rupture of membranes. Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Length of latency with preterm premature rupture of membranes before 32 weeks' gestation. Duration of the latency period in preterm premature rupture of the membranes. Preterm premature rupture of the membranes. Length of latency with preterm premature rupture of membranes. Association of fetal growth restriction with neurocognitive function after repeated antenatal betamethasone treatment vs placebo. Antenatal corticosteroids for preterm premature rupture of membranes: single or repeat course. The clinical use of corticosteroids in pregnancy. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Maternal intramuscular dexamethasone versus betamethasone before preterm birth. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Antenatal dexamethasone for early preterm birth in low-resource countries. Antenatal corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Antenatal corticosteroid therapy and blood pressure at 14 years of age in preterm children. Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. Persistent effects of antenatal synthetic glucocorticoids on endocrine stress reactivity from childhood to adolescence. Long-term impacts of prenatal synthetic glucocorticoids exposure on functional brain correlates of cognitive monitoring in adolescence. Prenatal betamethasone exposure and psychopathology risk in extremely low birth weight survivors in the third and fourth decades of life. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries.",
  "system_prompt": "You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.",
  "guideline_id": "bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf",
  "guideline_title": "BJOG - 2022 - Stock - Antenatal corticosteroids to reduce neonatal morbidity and mortality.pdf"
}

A: Here is the analysis of the clinical note against the provided guideline, with recommendations for improvement:

### Very Important Recommendations
1. **Additional information needed** - Document the specific corticosteroid regimen administered (dexamethasone phosphate or betamethasone sodium phosphate/acetate mix) and the timing of administration relative to potential delivery.  
   Reason: The guideline specifies the optimal dose and route (24mg dexamethasone phosphate or 24mg betamethasone sodium phosphate/acetate mix IM) and emphasizes effectiveness within 48 hours prior to birth (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  

2. **Improved patient advice** - Provide explicit counseling to the patient about the benefits (reduced neonatal respiratory distress and mortality) and risks (potential neonatal hypoglycemia, long-term metabolic effects) of antenatal corticosteroids.  
   Reason: The guideline highlights the importance of informed discussions, especially regarding risks in late preterm (35+0 to 36+6 weeks) and special populations (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  

### Somewhat Important Recommendations
1. **Different management plan** - Consider serial hemoglobin monitoring more frequently (e.g., every 12â24 hours) given the drop from 11.4 to 10.8 g/dL and active bleeding risk.  
   Reason: While not explicitly stated in the guideline, close monitoring aligns with general principles of managing antepartum hemorrhage and anemia (implied in guideline sections on high-risk pregnancies).  

2. **Additional information needed** - Document whether a discussion occurred about the potential need for repeat corticosteroids if delivery is delayed beyond 7 days.  
   Reason: The guideline notes limited evidence for repeat courses but recommends considering them if the risk of preterm birth persists (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  

### Less Important Recommendations
1. **Improved patient advice** - Offer written information or support group links about placenta previa and corticosteroids.  
   Reason: The guideline mentions providing support resources, though this is not critical for immediate management (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  

2. **Additional information needed** - Document fetal growth percentile (if available) to assess small-for-gestational-age risk, as corticosteroids may have limited evidence in this population.  
   Reason: The guideline notes uncertainty about corticosteroids in growth-restricted infants (guideline ID: bjog-2022-stock-antenatal-corticosteroids).  

### Unimportant Recommendations
1. **Different management plan** - Consider adding a note about anesthetic consultation timing (e.g., "within 24 hours") for clarity.  
   Reason: While useful for workflow, this is not guideline-mandated and does not impact safety.  

---  
**Summary**: The note largely aligns with the guideline, but critical gaps include documentation of the corticosteroid regimen and patient counseling. Close monitoring and explicit discussions about risks/benefits are prioritized.

--- Token Usage Report ---
Prompt tokens: 2116
Completion tokens: 625
Total tokens: 2741
Estimated cost: $0.001371